Basilea Pharmaceutica AG/ CH0011432447 /
| 20/05/2024 19:51:48 | Chg. +3.7000 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 48.1500USD | +8.32% | 200 Turnover: 9,630 |
-Bid Size: - | -Ask Size: - | 634.62 mill.USD | - | - |
GlobeNewswire
16/05
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
03/05
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
24/04
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
09/04
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
04/04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
11/03
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
13/02
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
19/01
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
11/12/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
20/11/2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
13/11/2023
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
31/10/2023
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
19/10/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
17/10/2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
02/10/2023
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire
28/09/2023
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire
08/03/2022
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire
15/02/2022
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
24/01/2022
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire
13/01/2022
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire
11/01/2022
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire
10/01/2022
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
